225 related articles for article (PubMed ID: 36432703)
1. Pheophorbide A-Mediated Photodynamic Therapy Potentiates Checkpoint Blockade Therapy of Tumor with Low PD-L1 Expression.
Tong Q; Xu J; Wu A; Zhang C; Yang A; Zhang S; Lin H; Lu W
Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36432703
[TBL] [Abstract][Full Text] [Related]
2. Combination of a novel heat shock protein 90-targeted photodynamic therapy with PD-1/PD-L1 blockade induces potent systemic antitumor efficacy and abscopal effect against breast cancers.
Kaneko K; Acharya CR; Nagata H; Yang X; Hartman ZC; Hobeika A; Hughes PF; Haystead TAJ; Morse MA; Lyerly HK; Osada T
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36171008
[TBL] [Abstract][Full Text] [Related]
3. Multifunctional Nanoparticles-Mediated PTT/PDT Synergistic Immune Activation and Antitumor Activity Combined with Anti-PD-L1 Immunotherapy for Breast Cancer Treatment.
Kong C; Xu B; Qiu G; Wei M; Zhang M; Bao S; Tang J; Li L; Liu J
Int J Nanomedicine; 2022; 17():5391-5411. PubMed ID: 36419717
[TBL] [Abstract][Full Text] [Related]
4. Photodynamic therapy synergizes with PD-L1 checkpoint blockade for immunotherapy of CRC by multifunctional nanoparticles.
Yuan Z; Fan G; Wu H; Liu C; Zhan Y; Qiu Y; Shou C; Gao F; Zhang J; Yin P; Xu K
Mol Ther; 2021 Oct; 29(10):2931-2948. PubMed ID: 34023507
[TBL] [Abstract][Full Text] [Related]
5. Enhancing Anti-PD-1/PD-L1 Immune Checkpoint Inhibitory Cancer Therapy by CD276-Targeted Photodynamic Ablation of Tumor Cells and Tumor Vasculature.
Bao R; Wang Y; Lai J; Zhu H; Zhao Y; Li S; Li N; Huang J; Yang Z; Wang F; Liu Z
Mol Pharm; 2019 Jan; 16(1):339-348. PubMed ID: 30452269
[TBL] [Abstract][Full Text] [Related]
6. Chemo-photodynamic therapy with light-triggered disassembly of theranostic nanoplatform in combination with checkpoint blockade for immunotherapy of hepatocellular carcinoma.
Xu J; Zheng Q; Cheng X; Hu S; Zhang C; Zhou X; Sun P; Wang W; Su Z; Zou T; Song Z; Xia Y; Yi X; Gao Y
J Nanobiotechnology; 2021 Oct; 19(1):355. PubMed ID: 34717654
[TBL] [Abstract][Full Text] [Related]
7. Acid-Activatable Versatile Micelleplexes for PD-L1 Blockade-Enhanced Cancer Photodynamic Immunotherapy.
Wang D; Wang T; Liu J; Yu H; Jiao S; Feng B; Zhou F; Fu Y; Yin Q; Zhang P; Zhang Z; Zhou Z; Li Y
Nano Lett; 2016 Sep; 16(9):5503-13. PubMed ID: 27525587
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 blockade potentiates the antitumor effects of ALA-PDT and optimizes the tumor microenvironment in cutaneous squamous cell carcinoma.
Zeng Q; Yang J; Ji J; Wang P; Zhang L; Yan G; Wu Y; Chen Q; Liu J; Zhang G; Wang X
Oncoimmunology; 2022; 11(1):2061396. PubMed ID: 35402079
[TBL] [Abstract][Full Text] [Related]
9. Combination of Photodynamic Therapy and a Flagellin-Adjuvanted Cancer Vaccine Potentiated the Anti-PD-1-Mediated Melanoma Suppression.
Hwang HS; Cherukula K; Bang YJ; Vijayan V; Moon MJ; Thiruppathi J; Puth S; Jeong YY; Park IK; Lee SE; Rhee JH
Cells; 2020 Nov; 9(11):. PubMed ID: 33171765
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Blockade Mediated by a Small-Molecule Nanoinhibitor Targeting the PD-1/PD-L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer.
Zhang R; Zhu Z; Lv H; Li F; Sun S; Li J; Lee CS
Small; 2019 Dec; 15(49):e1903881. PubMed ID: 31702880
[TBL] [Abstract][Full Text] [Related]
11. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
12. Dual-Sensitive PEG-Sheddable Nanodrug Hierarchically Incorporating PD-L1 Antibody and Zinc Phthalocyanine for Improved Immuno-Photodynamic Therapy.
Su Z; Xiao Z; Huang J; Wang Y; An Y; Xiao H; Peng Y; Pang P; Han S; Zhu K; Shuai X
ACS Appl Mater Interfaces; 2021 Mar; 13(11):12845-12856. PubMed ID: 33709684
[TBL] [Abstract][Full Text] [Related]
13. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
14. Drug-loaded microbubble delivery system to enhance PD-L1 blockade immunotherapy with remodeling immune microenvironment.
Zheng J; Huang J; Zhang L; Wang M; Xu L; Dou X; Leng X; Fang M; Sun Y; Wang Z
Biomater Res; 2023 Feb; 27(1):9. PubMed ID: 36759928
[TBL] [Abstract][Full Text] [Related]
15. Aerosolized immunotherapeutic nanoparticle inhalation potentiates PD-L1 blockade for locally advanced lung cancer.
Liu Y; Crowe WN; Wang L; Petty WJ; Habib AA; Zhao D
Nano Res; 2023 Apr; 16(4):5300-5310. PubMed ID: 37228440
[TBL] [Abstract][Full Text] [Related]
16. Reversing Immune Suppression and Potentiating Photothermal Immunotherapy via Bispecific Immune Checkpoint Inhibitor Loaded Hollow Polydopamine Nanospheres.
Guo K; Chen D; Ren S; Younis MR; Teng Z; Zhang L; Wang Z; Tian Y
ACS Appl Mater Interfaces; 2023 Mar; ():. PubMed ID: 36881613
[TBL] [Abstract][Full Text] [Related]
17. Combinatorial therapeutic approaches of photodynamic therapy and immune checkpoint blockade for colon cancer treatment.
Hao Y; Chung CK; Gu Z; Schomann T; Dong X; Veld RVHI'; Camps MGM; Ten Dijke P; Ossendorp FA; Cruz LJ
Mol Biomed; 2022 Aug; 3(1):26. PubMed ID: 35974207
[TBL] [Abstract][Full Text] [Related]
18. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
[TBL] [Abstract][Full Text] [Related]
19. Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy.
Lu CS; Lin CW; Chang YH; Chen HY; Chung WC; Lai WY; Ho CC; Wang TH; Chen CY; Yeh CL; Wu S; Wang SP; Yang PC
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243934
[TBL] [Abstract][Full Text] [Related]
20. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
